Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Five-Year Safety Evaluation of Maraviroc in HIV-1â

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154928
(Total Views: 440)
Posted On: 06/11/2019 6:38:35 AM
Posted By: plavac
Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients

https://journals.lww.com/jaids/fulltext/2014/...in.11.aspx

Given the unique mechanism of action of CCR5 antagonists, and the potential for longer-term safety issues, the US Food and Drug Administration requested extended 5-year follow-up for all study subjects receiving these compounds. In this study, we report the pooled safety findings from the MOTIVATE 1 and MOTIVATE 2 phase 3 studies for >5 years, the longest-term safety data available with a CCR5 antagonist.

In summary, in a population of HIV-infected treatment-experienced patients with >5 years of exposure to maraviroc, the incidence of death and other selected clinical events, including hepatic failure, malignancies, and myocardial infarctions, was low, and no new safety signals were reported. Maraviroc appears generally safe and well tolerated for at least 5 years in treatment-experienced patients.

Ultimately, a total of 938 study subjects (including 98 study subjects originally randomized to placebo) received maraviroc and contributed to a total maraviroc exposure of 2639 patient-years with a median exposure of 908 days (range, 1–2220 days).


(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us